Cobimetinib (Cotellic) is now approved as part of a combination treatment with Vemurafenib (Zelboraf) for advanced melanoma

Last Updated on

November 13, 2015 – The American Food and Drug Administration (FDA) just approved Cobimetinib (Cotellic) to be used in combination with Vemurafenib (Zelboraf) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). Already in September 2015, the European Medicines Agency (EMA) issued a positive opinion for approval of Cobimetinib (Cotellic) for the same indication.

Melanoma is the most aggressive and dangerous form of skin cancer. It forms in the skin cells that develop the skin’s pigment and if not diagnosed early, the cancer

Melanoma

Melanoma

is likely to spread to other parts of the body. Cobimetinib (Cotellic) works by blocking the activity of an enzyme known as MEK, which is part of a larger signaling pathway (the Ras-Raf-MEK-ERK pathway). Abnormal activity of signaling pathways can lead to cancer. Cobimetinib (Cotellic) prevents or slows cancer cell growth. Vemurafenib (Zelboraf) in itself is a BRAF inhibitor that affects a different part of the same pathway and was approved in the US in 2011 to treat patients with melanoma that has spread to other parts of the body or cannot be removed by surgery, whose tumors express a gene mutation called BRAF V600E, as detected by an FDA approved test. Health care providers should confirm the presence of BRAF V600E or BRAF V600K mutation in their patients’ tumor specimens using one of the available FDA approved tests prior to starting treatment with Cobimetinib (Cotellic) in combination with Vemurafenib (Zelboraf).

As clinical basis for the FDA approval, the safety and efficacy of Cobimetinib (Cotellic) taken in combination with Vemurafenib (Zelboraf) were demonstrated in a randomized clinical study of 495 patients with previously untreated, BRAF V600 mutation-positive melanoma that is advanced or cannot be removed by surgery. All study participants received Vemurafenib (Zelboraf) and were then randomly selected to also take either Cobimetinib (Cotellic) or a placebo. On average, patients taking Cobimetinib (Cotellic) plus Vemurafenib (Zelboraf) experienced a delay in the amount of time it took for their disease to worsen (approximately 12.3 months after starting treatment) compared to approximately 7.2 months after starting treatment for those taking Vemurafenib (Zelboraf) only. In addition, patients taking Cobimetinib (Cotellic) plus Vemurafenib (Zelboraf) lived longer, with approximately 65 percent of patients alive 17 months after starting treatment as compared to half of those taking vemurafenib only. Additionally, 70 percent of those taking Cobimetinib (Cotellic) plus Vemurafenib (Zelboraf) experienced complete or partial shrinkage of their tumors, compared to 50 percent among those taking Vemurafenib (Zelboraf) plus placebo.

Cobimetinib (Cotellic) may cause severe adverse effects including damage to the heart muscle (cardiomyopathy) or to other muscles (rhabdomyolysis), new skin tumors (primary cutaneous malignancies), eye disease (retinal detachment), severe skin rash, liver damage (hepatotoxicity), hemorrhage and severe skin rash due to increased sensitivity to sunlight (photosensitivity). People taking Cobimetinib (Cotellic) should avoid sun exposure, wear protective clothing, and a broad spectrum ultraviolet A/ultraviolet B sunscreen to protect against sunburn. Women taking Cobimetinib (Cotellic) should use effective contraception, as the medication can cause harm to a developing fetes. Other than that, the most common side effects of treatment with Cobimetinib (Cotellic) in combination with Vemurafenib (Zelboraf) are diarrhea, nausea, fever (pyrexia) and vomiting.

See here an early commentary on the therapy of Cobimetinib (Cotellic) in combination with Vemurafenib (Zelboraf):

For Vemurafenib (Zelboraf) see also two earlier posts on Thasso Post here and here. Particularly the second article addressed the question of secondary tumors being associated with Vemurafenib (Zelboraf) therapy.  As we have learned above, the occurrence of new skin tumors (primary cutaneous malignancies) is still a problem also with Cobimetinib (Cotellic) in combination with Vemurafenib (Zelboraf).

Tags: , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

@peepso_user_30549(sajibuni)
Hello Everyone out there,I am here to give my testimony about a Herbalist doctor who helped me . I was infected with HERPES SIMPLEX VIRUS five years ago, i went to many hospitals for cure but there was no solution, so I was thinking how can I get a solution out so that my body can be okay. One day I was in the river side thinking where I can go to get solution. so a lady walked to me telling me why am I so sad and i open up all to her telling her my problem, she told me that she can help me out, she introduce me to a doctor who uses herbal medication to cure HERPES SIMPLEX VIRUS and gave me his email, so i mail him. He told me all the things I need to do and also give me instructions to take, which I followed properly. Before I knew what is happening after two weeks the HERPES SIMPLEX VIRUS that was in my body got vanished . so if you are also heart broken and also need a help, you can also email him at dr.chalaherbalhome@gmail.com or Contact him today on whatsapp number… Read more
3 weeks ago 3 weeks ago

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Citizen science and paddle surf to study microplastic pollution in Barcelona's coastline February 27, 2020
    A team of the University of Barcelona has studied for the first time the presence of microplastics in the coasts of Barcelona, with the collaboration of the citizens gathering scientific samples. The study, published in the journal Science of Total Environment, is a pioneer citizen science study worldwide, since it analyses a hard-access area for […]
  • Celiac disease might be cured by restoring immune tolerance to gliadin February 27, 2020
    Celiac disease affects 0.3-2.4% of people in most countries world-wide, and approx. 2% in Finland. Celiac patients suffer from a variety of symptoms, typically intestinal complaints, such as diarrhea, but are often symptom-free. Immunologist Tobias Freitag co-developed and tested nanoparticles containing gliadin for the immunomodulatory treatment of celiac disease in Professor Seppo Meri's research group […]
  • Abnormal growth of bacterial cells could be linked to anti-microbial resistance February 27, 2020
    Scientists from the University of Surrey have identified mutations in a gene in an Escherichia coli (E.coli) model that could help explain a form of anti-microbial resistance (AMR) known as 'persistence'.
  • Study unravels how our immune system deals with fungal and viral infections February 27, 2020
    The body's immune response to fungal infections changes when a patient is also infected by a virus, according to new research which investigated the two types of infection together for the first time.
  • How the brain separates words from song February 27, 2020
    The perception of speech and music -- two of the most uniquely human uses of sound -- is enabled by specialized neural systems in different brain hemispheres adapted to respond differently to specific features in the acoustic structure of the song, a new study reports.
Top